Director: The special effects are too expensive, so I had to make real shots

Chapter 74 Boss, he is real, I cry to death

Chinese name: Ponatinib
English name: Ponatinib
Chemical formula: C29H27F3N6O
Molecular weight: 532.56
Acidity coefficient: 12.99±0.70
Drug use: Effectively acts on the multi-target inhibition of Abl, PDGFRα, VEGFR2, FGFR1 and Src.

Xu Nuo also had a new understanding of the drug treatment of chronic myelogenous leukemia after gaining an in-depth understanding of the new generation of tyrosine kinase inhibitor drug "ponatinib" synthesized by Professor Huang Wenqiang's team.

Actually.

This Ponatinib was developed in the previous life on the earth and was approved for marketing as a third-generation tyrosine kinase inhibitor.

It's just because the technology of Blue Star in this parallel world is relatively lagging behind, and in the field of drugs for the treatment of chronic myelogenous leukemia, it still stays on drugs such as imatinib.

So ponatinib is a more powerful new drug for chronic myelogenous leukemia.

"Professor Huang, how much advantage does our Ponatinib have in terms of efficacy compared with the imatinib of the European Nori Pharmaceutical Group?"

Xu Nuo asked Professor Huang Wenqiang seriously.

After all, this is not Xu Nuo's professional field, so I still have to ask Professor Huang Wenqiang for advice.

"Compared with imatinib, our new drug can obtain cytogenetic and molecular responses more quickly, especially deep molecular responses, and should be able to achieve better effects on patients with moderate and high risk in the chronic phase , At the same time, it is more likely to reduce the progression of the disease. As for the specifics, we need to wait for our new drug to undergo clinical trials before we can get more detailed data."

Huang Wenqiang introduced.

Here Professor Huang Wenqiang used the word "should" for the drug effect, because this is only the comparative information obtained during the research and development process. In fact, it has to be confirmed by clinical trials before it can be said with certainty that the drug effect is better than that of the drug. Strong imatinib.

"What about the side effects?"

Xu Nuo asked again.

As a synthetic chemical drug, if it has a good effect on the disease, then there will definitely be side effects, which are just a big or small problem.

After all, there is a saying.

Three-drug.

The same is true for ponatinib, which may be more effective than imatinib of the European Norry Pharmaceutical Group, but it is not an invincible medicine after all.

As Professor Huang Wenqiang said just now, it can inhibit multi-target receptors and greatly reduce the progression of CML.

That is to say, when patients use this new drug, CML will basically not continue to be severe, and it can effectively stabilize the condition.

So as long as you insist on taking it, patients in the early and middle stages are basically no different from normal people, and patients at medium and high risk can also stabilize their condition and stop deteriorating.

"Mr. Xu, in the process of research, we did find that Ponatinib has certain side effects for patients, for example, it may have adverse reactions on cardiovascular and thrombosis. Xiao Yang, you put our Ponatinib drug Bring over the research data on side effects and report to the boss."

Huang Wenqiang called out to a young man in the team.

"Professor, boss."

Young man Yang Jin came up to Xu Nuo with a tablet in his hand: "During the research on the synthesis of Ponatinib, we also made some corresponding research on the side effects of chemical drugs in the treatment of chronic myelogenous leukemia. The possible side effects are congestive heart failure, hypertension, arrhythmia and bone marrow suppression, etc.

"So are these side effects big?"

Xu Nuo knew that things like high blood pressure and arrhythmia were fine if they were milder, but if they had a greater impact, they might not be very good.

"The side effects of congestive heart failure, high blood pressure, and arrhythmia we studied should be at the level of monitoring. The side effects are not too great, and health monitoring is required. Bone marrow suppression may lead to thrombocytopenia and neutropenia. , and anemia, etc., may need to interrupt or reduce the dose at that time."

Yang Jin continued to explain.

At this time, Huang Wenqiang said seriously: "These possible side effects will ultimately require more detailed data in the clinical trial response. I prefer that the side effects will be lower in clinical practice."

Xu Nuo probably understood.

Although it seems that there are indeed many side effects, such as affecting blood pressure, arrhythmia, and bone marrow suppression.

However, these side effects are completely acceptable for the therapeutic effect of ponatinib.

To put it simply, this drug can save your life and basically stop your disease from getting worse, but you need to maintain periodic safety monitoring of your blood pressure, heart rate, platelets, etc.

"Then when can I apply for the first phase of clinical trials?"

Xu Nuo wanted to know when the clinical trial could be applied to start after learning about the pharmacological mechanism, drug efficacy, drug side effects and other information.

Huang Wenqiang replied: "For clinical trials, we will collect and sort out the data before the clinical trials in the past few days. After the National Day, we can apply to the National Drug Administration for the first phase of clinical trials."

Under normal circumstances, the birth of a new drug has a strict process.

The first is to choose a disease, and then conduct drug exploration based on this disease.

Xu Nuo's biomedical laboratory naturally chose chronic myelogenous leukemia.

This is also the direction that Professor Huang Wenqiang has been working on with these young graduate students and doctoral students before, but the progress is slow because of limited funds.

And after coming to Xynuo's biomedical laboratory, coupled with the addition of Xyno's exchange [new generation tyrosine kinase inhibitor], it is basically equivalent to skipping the drug discovery and drug research. two stages.

After a new drug is synthesized, the next step is clinical trials.

However, before clinical trials, preclinical safety, evaluation, and toxicity studies need to be conducted. It is obvious from Xu Nuo's inquiry just now that Professor Huang Wenqiang and the others are already doing this.

"Okay, if you need anything in the laboratory, just tell me, I look forward to your good news."

"Mr. Xu, don't worry, we will definitely develop this new drug as soon as possible." Yang Jin said confidently.

At the boss Xu Nuo's place, Yang Jin and his top medical students have found the true value of life.

Because this new tyrosine kinase inhibitory drug can save countless chronic myelogenous leukemia patients at home and abroad. These patients have been taking expensive medicines all year round and have almost no hope in life.

Once this new drug comes out, its efficacy and pricing will be much more cost-effective than imatinib.

According to Yang Jin's estimation, if the clinical trials of this drug are completed and approved for marketing, the price of tyrosine kinase inhibitors can be lowered to less than [-] yuan.

This is definitely good news for patients with chronic myelogenous leukemia.

Just imagine, the price of a box of medicine was as high as 24000 yuan before, and you need to eat one box a month.

And when ponatinib is on the market, a box of medicine only costs a few thousand yuan, and a box of medicine can be used for more than a month, so the cost of taking medicine will drop all of a sudden.

And even if the medicine is expensive for several thousand yuan, that’s okay. Our own domestic medicine has a good chance to join the medical insurance. At that time, for the patients, they may be able to eat ponatinib for about a thousand yuan. up.

In fact, the medical insurance negotiation team has been working hard for these years to negotiate with the European Nori Pharmaceutical Group to join the medical insurance.

It's just that the European Nuori Pharmaceutical Group has been dragging its feet. They are unwilling to give up such a large pharmaceutical market in Huaguo, because the data shows that the number of patients with chronic myelogenous leukemia in Huaguo is increasing every year.

Such a huge, rising market, how could the European guys give up so easily.

This is also the main reason why the price of imatinib of the European Nori Pharmaceutical Group has remained high and has not been covered by medical insurance.

Anyway, the patients in China who suffer a lot can make a lot of money. For European capitalists, what reason is there to show mercy?

"Boss Xu, go slowly."

"Everyone has worked hard, and I will give you bonuses at the end of the year."

Xu Nuo encouraged Yang Jin and the others.

"thank you boss!"

All the young people in the laboratory were very excited when they heard the boss Xu Nuo said that there would be a bonus at the end of the year.

They work in real biomedical laboratories, and the salaries they get are already very high, plus bonuses, which directly makes each of them feel that they have chosen to study medicine all their lives, and work hard to study postgraduate studies and engage in scientific and technological research. Totally worth it.

After leaving the biomedical laboratory.

Xu Nuo was about to take another turn in the company, so he said to his assistant Wen Ruohan, "Xiaowen, take me to various departments of the company to have a look."

however.

After Xu Nuo's voice fell, there was no response for a long time.

what happened?

"Xiaowen?"

Xu Nuo stopped walking and called out to his assistant Wen Ruohan behind him.

Still no response.

Xu Nuo had no choice but to turn around, but found that Wen Ruohan was not behind him, and seemed to be in a daze not far away.

"Xiaowen, what are you doing there?"

Xu Nuo stepped forward, only to realize that Wen Ruohan was not in a daze, but sobbing secretly, actually crying?
"what happened?"

Xu Nuo looked bewildered, and quickly asked, "Why are you still crying?"

"Boss, so it turns out, our...this"

Wen Ruohan was sobbing, and his speech became difficult.

"Don't cry, just say it, what is this?"

Xu Nuo suddenly became serious and asked.

"This is it. The biomedical laboratory, it turns out, is for the research and development of drugs for chronic myelogenous leukemia, blah blah." Wen Ruohan tried her best to control her crying, raised her head and looked at Xu Nuo with tears in her eyes: "Boss, did you already know me?"

Wen Ruohan is not stupid, although she didn't understand the multi-targets, induced pockets, and kinase domain mutants that Professor Huang Wenqiang communicated with the boss in the laboratory just now.

But she understood that the drug studied by the biomedical laboratory was compared with imatinib.

Of course, Wen Ruohan knew what imatinib was, because the medicine she was taking every month was imatinib.

After thinking about it together, Wen Ruohan naturally understood that the boss's biomedical laboratory was developing a new drug for the treatment of chronic myelogenous leukemia.

"Oh, this matter."

When Xu Nuo heard it, he immediately understood why Xiaowen was crying, and then said with a light smile: "Yes, I accidentally saw your hospital examination report last time, and knew that you had chronic myelogenous leukemia, but it's okay, it's not What's the big deal, isn't our new drug ponatinib already developed, and after the successful completion of clinical trials, you can get affordable drugs."

"Whooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo!"

Hearing what the boss said, at this moment, Wen Ruohan couldn't hold back any longer.

Tears from the lacrimal glands continued to overflow, and the whole person crashed into the boss's arms, crying fiercely while hugging the savior.

"Ehhh!"

Xu Nuo was bumped suddenly by this little assistant, not to mention that his chest was always hurting, the most important thing was that the girl was still holding him and crying non-stop, Xu Nuo didn't know what to do for a while.

and also.

Xiaowen, do you have some misunderstandings?

I spent money and entertainment on this Ponatinib, really just to make "I'm Not the God of Medicine".

Good guy, when I came to you, I was brainwashed into thinking that I was developing a new drug for you?
But the atmosphere is here.

Xu Nuo can't always tell the truth to the little girl, it's impossible, because it involves the secrets of his own system to some extent.

"Okay, okay, don't cry, you're still crying when you're an adult, and if you cry again, I won't do my butler job for you."

Xu Nuo released a ruthless move, which stopped Wen Ruohan from sobbing and crying.

I saw Wen Ruohan raised his head, wiped away the tears from the corners of his eyes, and said with pear blossoms all over his body, "Boss, I am very moved."

"I don't need to be touched. Wouldn't it be better to work hard in the future and work hard to repay the boss?"

"Yeah, I'll definitely do a good job!"

Wen Ruohan's eyes, which were still full of tears, became more determined.

"Okay, let's go, take me to various departments of the company to have a look."

Xu Nuo turned around and walked towards the elevator.

Wen Ruohan quickly trotted up and followed.

After walking into the elevator, Xu Nuo saw that his little assistant hadn't fully recovered from the emotional crying just now, so he casually changed the subject and asked, "The National Day holiday is coming soon, where are you going to go?"

"I have an appointment with my best friend to go to Dali."

After Wen Ruohan answered, he asked, "How about you, boss?"

"I don't have any travel plans. I just took advantage of this vacation to build a smart robotic arm in a modified garage."

"Oh, then I must cook for the boss."

Wen Ruohan heard the words, took out her mobile phone while talking, opened WeChat, and sent a voice message to her best friend: "Bao'er, I won't go to Dali, anyway, you have a boyfriend to accompany you, I wish you some fun Have fun."

Xu Nuo:? ? ? ? ?
"Xiaowen, let's just say, there's no need for that, just go when you want to play." Xu Nuo said dumbfounded.

"No."

Wen Ruohan shook her head, her gaze was firm: "Boss, you can concentrate on making intelligent robotic arms, doing laundry, cooking, making beds and making quilts, and all other tasks are entrusted to me. I have already refunded the ticket!"

Xu Nuo said, this is not because I forced to work overtime!

It was her own initiative!
(End of this chapter)